Weekly Funding Opportunities

[Med Research]

The last one of 2020! Happy Holidays!

William T. Grant Foundation: Research Grants<https://urldefense.com/v3/__http://wtgrantfoundation.org/grants__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdlV4L_34$ >
We fund research that increases understanding in one of our two focus areas:

  *   programs, policies, and practices that reduce inequality<https://urldefense.com/v3/__http://wtgrantfoundation.org/focus-areas/reducing-inequality__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdIo9gjXA$ > in youth outcomes, and
  *   strategies to improve the use of research evidence<https://urldefense.com/v3/__http://wtgrantfoundation.org/focus-areas/improving-use-research-evidence__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdElwxV70$ > in ways that benefit youth.
The Reducing Inequality program supports high-quality field-initiated studies from a range of disciplines and methodologies that are relevant to policies and practices that affect the lives of young people between the ages of 5 and 25 in the United States. Through the program, grants of up to $600,000 over a period of up to three years will be awarded in support of major research designed to build, test, or increase understanding of programs, policies, or practices with the potential to reduce inequality in the academic, social, behavioral, or economic outcomes of young people. Descriptive studies that clarify mechanisms for reducing inequality or elucidate how or why a specific program, policy, or practice operates to reduce inequality are welcomed. The foundation prioritizes studies about reducing inequality on the basis of race, ethnicity, economic standing, language, minority status, or immigrant origin. It also welcomes studies from a range of disciplines, fields, and methodologies and encourages investigations into various systems, including justice, housing, child welfare, mental health, and education. Competitive proposals often incorporate data from multiple sources and often involve multidisciplinary teams. In addition to financial support, grantees receive significant time and capacity-building resources from the foundation. Projects led by African American, Latinx, Native American, and Asian Pacific American researchers are encouraged. The Improving the Use of Research Evidence program supports high-quality field-initiated studies that identify, build, and test strategies to enhance the use of research evidence in ways that benefit youth (ages 5 to 25 in the US). We are particularly interested in research on improving the use of research evidence by state and local decision makers, mid-level managers, and intermediaries. Some investigators will focus on the strategies, relationships, and other supports needed for policy and practice organizations to use research more routinely and constructively. Others may investigate structures and incentives within the research community to encourage deep engagement with decision makers. Still other researchers may examine activities that help findings inform policy ideas, shape practice responses, and improve systems.
Letters of inquiry to either program due January 13, 2021; May 5, 2021; August 4, 2021. Med-RA deadline to receive draft documents for January due date: January 4.

Alzheimer’s Drug Discovery Foundation: Program to Accelerate Clinical Trials (PACT)<https://urldefense.com/v3/__http://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdKcJBcCU$ >
The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.
Stage of development:
1. Early-stage human clinical trials including:

  *   Phase 0 micro- or sub-therapeutic-dosing studies
  *   Phase 1 trials in healthy subjects
  *   Biomarker-based proof-of-concept studies (generally phase 1b or phase 2a trials) designed to assess target engagement and downstream pharmacologic effects
2. Regulatory studies including:

  *   Non-GLP and GLP pharmacology and toxicology studies, pre-formulation, and GMP manufacture required for investigational new drug (IND) and clinical trial authorization (CTA) preclinical packages. Funding is available for preparation of traditional and exploratory IND applications
  *   Long-term toxicology studies to enable longer-term dosing in phase 2 trials
  *   GMP manufacturing and testing of clinical grade drug required to move into phase 2 or phase 3 trials
For clinical trial applications, if IND-enabling work is in progress, funding for clinical studies would be contingent upon an IND (or equivalent) being granted and full review of the data package.
Type of therapy: Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered.
Drug mechanisms or modes of action: Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to:

  *   Epigenetics
  *   Inflammation
  *   Mitochondrial & metabolic function
  *   Neuroprotection
  *   Proteostasis
  *   Synaptic activity and neurotransmitters
  *   Vascular function
  *   Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)
  *   Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process
  *   Please note: Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered
Average Duration: Varies
Average Award: Up to $3 million; no IDC
Letter of intent due February 5, 2021; May 28, 2021; October 1, 2021. Med-RA deadline to receive draft documents for February due date: January 25.

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 and R61 / R33 Clinical Trial Optional)
R34<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-097.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAduh7fpQI$ >
R61 / R33<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-098.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdn6v3Sqo$ >
These Funding Opportunity Announcements focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of these FOAs is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via these mechanisms will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies.
Due February 19, 2021; June 17, 2021; October 19, 2021; February 17, 2022; June, 17, 2022; October 18, 2022; February 17, 2023; June 19, 2023; and October 17, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 8.

Mood Disorders in People Living with HIV: Mechanisms and Pathways (R21 / R01 Clinical Trial Optional)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-117.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdbhJapS0$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-116.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAd6CEKLm8$ >
The purpose of these Funding Opportunity Announcements (FOAs) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial, and structural factors contributing to mood disorders in people living with HIV. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
Due March 10, 2021. Med-RA deadline to receive draft documents: February 25.

NSF Integrative Research in Biology (IntBIO)<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21543/nsf21543.htm__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdmKC6au0$ >
The Integrative Research in Biology program replaces the Rules of Life track. This solicitation invites submission of collaborative proposals that tackle bold questions in biology and require an integrated approach to make substantive progress. Integrative biological research spans subdisciplines and incorporates cutting-edge methods, tools, and concepts from each to produce groundbreaking biological discovery. The research should be synergistic and produce novel, holistic understanding of how biological systems function and interact across different scales of organization, e.g., from molecules to cells, tissues to organisms, species to ecosystems and the entire Earth. Such knowledge is critical to inform solutions to societal challenges, including natural resource management, resilience to environmental change, and global food security. Outcomes from integrative research will also inform and guide the development of new technologies that drive the nation’s bioeconomy.
Due March 16, 2021 and January 25, 2021. Med-RA deadline to receive draft documents for March due date: March 3.

Enabling Discovery through GEnomic Tools (EDGE)<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21546/nsf21546.htm__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdjgL62Eg$ >
Through the Enabling Discovery through GEnomics (EDGE) program, the National Science Foundation (NSF) and the National Institutes for Health (NIH) support research to advance understanding of comparative and functional genomics. The EDGE program supports the development of innovative tools, technologies, resources, and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and phenotypes. The EDGE program also supports functional genomic research that addresses the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. These goals are essential to uncovering the rules that underlie genomes-to-phenomes relationships and predict phenotype,. The goals also support the NHGRI priority to establish the roles and relationships of all genes and regulatory elements in pathways, networks, and phenotypes.
The EDGE program will accept proposals to two submission tracks:
FUNCTIONAL GENOMIC TOOLS (FGT) TRACK: Proposals submitted to this track should aim to develop and provide proof-of-concept tests of functional genomic tools and infrastructure to enable direct tests of hypotheses about gene function in diverse species for which such tools and infrastructure are presently unavailable. Investigators may use taxonomic, question-based, and/or technology-based strategies to develop tools and approaches that will be employed by larger communities of researchers. Projects may include instrumentation development followed by proof-of-concept testing in the context of developing functional genomic tools to enable direct tests of gene function. Examples of relevant objectives for plants, animals, microbes, viruses, or fungi for which such tools and infrastructure are presently unavailable include, but are not limited to:

  *   Development of mutant libraries and/or high-quality reference genomes;
  *   Expansion of the use of gene editing, knock-out, and overexpression approaches for manipulating individual genes or interrogating multiple genes simultaneously in diverse organisms;
  *   Development of approaches to test gene function in a variety of targeted, single cells in organisms;
  *   Generalizable high-throughput phenotyping methods;
  *   Innovative approaches for establishing function of single or networks of genes; and
  *   Development and testing of transformation approaches.
COMPLEX MULTIGENIC TRAITS (CMT) TRACK: Proposals submitted to this track should include hypothesis-driven research that advances understanding of the relationship between genomes and complex multi-genic traits, toward the goal of predicting phenotypes across diverse contexts, including environmental, developmental, social, and/or genomic contexts. Successful proposals may include the development of theory and/or analytical approaches to achieve the scientific goal. The EDGE program recognizes that many of the traits of interest to biologists are quantitative in nature and are controlled by many genes of small effect and that understanding complex traits requires systems-level analysis of the underlying gene regulatory networks that goes beyond linking individual genes with said traits. Submissions to the COMPLEX MULTIGENIC TRAITS TRACK should emphasize the contribution of genome-wide factors that impact expression of a phenotype.
Submissions to this track may include but are not limited to:

  *   Systems-level analysis of the gene regulatory networks underlying complex traits;
  *   Elucidation of the causal connections across levels of biological organization that underlie complex multigenic traits;
  *   New or innovative analytical approaches to linking genes and complex traits; and
  *   Multi-genome/epigenome interactions with the environment towards the goal of predicting complex organismal phenotypes across contexts.
Budget requests should be commensurate with the goals of the project. The EDGE program expects to make awards covering the full range of budget requests commensurate with the size and scope of each project.
Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.

Aging Effects on Osteoimmunology (R01 Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-002.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdIXuLXOY$ >
This Funding Opportunity Announcement (FOA) solicits grant applications that will examine the role of aging in the interactions between the immune systems and skeletal systems in animal models. Research projects that will determine the mechanisms involved in how both aging of the bone marrow niche and immunosenescence impact these interactions, leading to pathological conditions in bone homeostasis, are the focus of this FOA.
Due June 15, 2021. Med-RA deadline to receive draft documents: June 2.

New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (UG3 / UH3 Clinical Trials Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-001.html__;!!PhOWcWs!kFp-xHZJNl-YTkOrB7aA7vMdJCoymCEDpSbhlWb_gg_clTzMyERjxAgguUu7XHeK3B24HPv75MAdBQN7DAw$ >
The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA will support intramural – extramural collaborations to develop additional physical modules that will enhance the platform’s capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.
Due July 8, 2021. Med-RA deadline to receive draft documents: June 24.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20201218/b9bdc955/attachment.html>